ArticleAmerican journal of nephrology2021
Impact of Polypharmacy on Health-Related Quality of Life in Dialysis Patients.
Article in American journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Association of intensive blood pressure management with cardiovascular outcomes in patients using multiple classes of antihypertensive medications: a post-hoc analysis of the STEP Trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Trial
- Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.Scientific reports · 2023Trial
- Comfort Needs of Renal Transplant Recipients: A Qualitative Analysis Guided by Kolcaba's Theory of Comfort.Journal of clinical nursing · 2026Article
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
- Prevalence, severity, and determinants of CKD-associated pruritus in a Swiss hemodialysis population with widespread use of hemodiafiltration: a cross-sectional study.BMC nephrology · 2025Observational
- Integrative Analysis of Drug Co-Prescriptions in Peritoneal Dialysis Reveals Molecular Targets and Novel Strategies for Intervention.Journal of clinical medicine · 2025Article
- Medication review interventions for adults living with advanced chronic kidney disease: A scoping review.British journal of clinical pharmacology · 2025Article
- Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Optimizing use of an electronic medical record system for quality improvement initiatives in hemodialysis: Review of a single center experience.Hemodialysis international. International Symposium on Home Hemodialysis · 2025Review
- Deprescribing in Dialysis: Operationalizing "Less is More" Through a Multimodal Deprescribing Intervention.Kidney medicine · 2024Article
- Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the National Unified Renal Translational Research Enterprise CKD (NURTuRE-CKD) cohort.Clinical kidney journal · 2024Article
- Polypharmacy and Quality of Life Among Dialysis Patients: A Qualitative Study.Kidney medicine · 2024Article
- Prevalence of polypharmacy and medication-related quality of life among adult patients in Al-Ahsa, Saudi Arabia.Journal of medicine and life · 2023Article
- Polypharmacy and the Change of Self-Rated Health in Community-Dwelling Older Adults.International journal of environmental research and public health · 2023Article
- The association between polypharmacy and health-related quality of life among non-dialysis chronic kidney disease patients.PloS one · 2023Article
- Health-related quality of life and its associated factors in patients with chronic obstructive pulmonary disease.PloS one · 2023Article
- Impact of phosphate binders on quality of life in dialysis patients: Results from the prospective Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes study.Nephrology (Carlton, Vic.) · 2022Article
- Polypharmacy and Health-Related Quality of Life/Psychological Distress Among Patients With Chronic Disease.Preventing chronic disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDialysis patients are often prescribed a large number of medications to improve metabolic control and manage coexisting comorbidities. However, some studies suggest that a large number of medications could also detrimentally affect patients' health-related quality of life (HRQoL). Therefore, this study aims to provide insight in the association between the number of types of medications and HRQoL in dialysis patients.
methodsA multicentre cohort study was conducted among dialysis patients from Dutch dialysis centres 3 months after initiation of dialysis as part of the ongoing prospective DOMESTICO study. The number of types of medications, defined as the number of concomitantly prescribed types of drugs, was obtained from electronic patient records. Primary outcome was HRQoL measured with the Physical Component Summary (PCS) score and Mental Component Summary (MCS) score (range 0-100) of the Short Form 12. Secondary outcomes were number of symptoms (range 0-30) measured with the Dialysis Symptoms Index and self-rated health (range 0-100) measured with the EuroQol-5D-5L. Data were analysed using linear regression and adjusted for possible confounders, including comorbidity. Analyses for MCS and number of symptoms were performed after categorizing patients in tertiles according to their number of medications because assumptions of linearity were violated for these outcomes.
resultsA total of 162 patients were included. Mean age of patients was 58 ± 17 years, 35% were female, and 80% underwent haemodialysis. The mean number of medications was 12.2 ± 4.5. Mean PCS and MCS were 36.6 ± 10.2 and 46.8 ± 10.0, respectively. The mean number of symptoms was 12.3 ± 6.9 and the mean self-rated health 60.1 ± 20.6. In adjusted analyses, PCS was 0.6 point lower for each additional medication (95% confidence interval [95% CI]: -0.9 to -0.2; p = 0.002). MCS was 4.9 point lower (95% CI: -8.8 to -1.0; p = 0.01) and 1.0 point lower (95% CI: -5.1-3.1; p = 0.63) for the highest and middle tertiles of medications, respectively, than for the lowest tertile. Patients in the highest tertile of medications reported 4.1 more symptoms than in the lowest tertile (95% CI: 1.5-6.6; p = 0.002), but no significant difference in the number of symptoms was observed between the middle and lowest tertiles. Self-rated health was 1.5 point lower for each medication (95% CI: -2.2 to -0.7; p < 0.001). DISCUSSION/
conclusionAfter adjustment for comorbidity and other confounders, a higher number of medications were associated with a lower PCS, MCS, and self-rated health in dialysis patients and with more symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.